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The tetrahydrofolate (THF) riboswitch regulates
folate transport and metabolism in a number of
Firmicutes by cooperatively binding two molecules
of THF. To further understand this riboswitch’s spec-
ificity for THF, binding and regulatory activity of a
series of THF analogs and antifolates were exam-
ined. Our data reveal that although binding is domi-
nated by the RNA’s interactions with the pterin
moiety, the para-aminobenzoic acid (pABA) moiety
plays a significant role in transcriptional regulation.
Further, we find that adenine and several other ana-
logs bind with high affinity by an alternative binding
mechanism. Despite a similar affinity to THF, adenine
is a poor regulator of transcriptional attenuation.
These results demonstrate that binding alone does
not determine a compound’s effectiveness in regu-
lating the activity of the riboswitch—a complication
in current efforts to develop antimicrobials that target
these RNAs.INTRODUCTION
Folate and its reduced derivatives are essential for normal
cellularmetabolism in all life (Jabrin et al., 2003). Reduced folates
such as tetrahydrofolate (THF) are critically important for single
carbon unit transfer reactions in the synthesis of methionine,
thymine, and purines (Scott and Weir, 1998). This has made
enzymes that synthesize and utilize folates major targets of
therapeutics including sulfonamides directed against folate
biosynthesis in bacteria (Bermingham and Derrick, 2002) and
methotrexate and related compounds that act as anticancer
agents (Gonen and Assaraf, 2012). Research into how folates
and their inhibitors act in the biological context has shown to
be one of the few fruitful endeavors for the development of
antibiotics (Bermingham and Derrick, 2002). Further studies
into how folates regulate gene expression in bacteria may offer
a new avenue to apply this proven set of molecules for the dis-
covery of novel antibiotics as well as further our understanding
of a unique RNA base regulatory system.
Inmany Firmicutes, genes involved in folate transport and syn-
thesis are regulated by an element located within their mRNAChemistry & Biology 21, 205leader called a riboswitch (Ames et al., 2010). These nonprotein
coding elements consist of an aptamer domain that directly
interacts with an effector molecule and a regulatory domain
that generally contains a secondary structural switch directing
the expression machinery (Barrick and Breaker, 2007; Breaker,
2012). Members of the THF riboswitch family (Rfam RF01831)
have a highly conserved aptamer domain with a secondary
structure containing a three-way junction motif and a pseudo-
knot (Figures 1A and 1B). Upon THF binding the aptamer
domain, the regulatory domain will either terminate transcription
or inhibit translation. This RNA was found to bind a variety of
reduced folates including tetrahydrofolate (THF), dihydrofolate
(DHF), and tetrahydrobiopterin (BH4) with high affinity while
strongly discriminating against folate (Ames et al., 2010). This
suggested that a key element of recognition between the RNA
and folates is the presence of a hydrogen bond donor at position
N8 established by the reduction of the pterin ring (Figure 1C)
(Ames et al., 2010).
To reveal the structural basis for reduced folate recognition,
two groups independently solved the structure of members of
the THF riboswitch family in complex with a THF derivative,
folinic acid (FA). The structure solved by the Patel group revealed
a single THF binding site in the three-way junction, suggesting to
the authors that the THF induces a long-range pseudoknot
whose formation directs the downstream regulatory switch
(Huang et al., 2011). In contrast, the structure presented by
the Batey laboratory revealed two THF binding sites, one in the
three-way junction that is identical to that observed in the
Patel structure, and another in the pseudoknot (Trausch et al.,
2011). Notably, in the Patel structure, near the pseudoknot, is
an artifact of crystallization involving strand exchange between
two neighboring molecules within the crystalline array of mole-
cules, but was dismissed as not relevant to the biological form
of the RNA (Huang et al., 2011). Conversely, it can be argued
that the second site observed by the Batey group is an artifact
of the high folinic acid concentration used in the crystallization
conditions. Thus, it remains an open question as to which struc-
ture is the most biologically relevant representative of the THF
family (Serganov and Patel, 2012).
Both structures reveal that reduced folates are primarily
recognized by the RNA through their pterin moiety (Huang
et al., 2011; Trausch et al., 2011). In the three-way junction
(3WJ) site, two bases within the P3 helical element form a base
triple-like interaction with the pterin, whereas the pABA moiety
forms a stacking interaction with a flipped-out conserved purine
(Figures 1B and 1D). The pseudoknot (PK) binding site is formed–216, February 20, 2014 ª2014 Elsevier Ltd All rights reserved 205
Figure 1. Structure of the THF Riboswitch
(A) Representation of the secondary structure of the THF riboswitch (THF in black, P1 in blue, P2 in orange, P3 in green, P4 in cyan, and pseudoknot in red).
(B) X-ray crystal structure of the THF riboswitch bound to 6S-folinic acid (4LVV).
(C) Chemical structure of 6S-tetrahydrofolate (6S-THF), emphasizing the pterin, para-aminobenzoic acid (pABA), and glutamyl moieties.
(D) The three-way junction (3WJ) binding site of the THF riboswitch bound to 6S-folinic acid shown from two angles to emphasize the hydrogen bonding to the
pterin ring (top) and interactions of the pABA moiety (below).
(E) The pseudoknot (PK) binding site of the THF riboswitch bound to 6S-folinic acid shown from two angles.
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J2/1. Similar to the 3WJ site, the PK site primarily interacts with
the pterin ring of THF, while the pABA moiety makes van der
Waals interactions with the backbone of the RNA (Figures 1B
and 1E). The observation that recognition is primarily mediated
through the reduced pterin was reinforced by calorimetric data
showing that guanine, whose ring system has an analogous
set of hydrogen bond acceptors and donors as reduced pterin,
can bind the THF riboswitch with nearly identical affinity at
10 mM magnesium ion concentration (Trausch et al., 2011).
Despite the two THF sites having nearly identical affinities for
the effector, they appear to have very different roles in transcrip-
tional attenuation. Although the wild-type Streptococcus mutans
(Smu) riboswitch did not function in a single-turnover in vitro tran-
scriptional termination assay, a common method for assessing
riboswitch activity, a chimera of the Smu aptamer and Bacillus
subtilis metE regulatory switch is strongly THF-responsive
(Trausch et al., 2011). Chimeric riboswitches have been validated
with numerous aptamer/expression platform pairings and found
to be an accurate reporter ligand-dependent regulatory activity
(Ceres et al., 2013a; Ceres et al., 2013b). In the context of the
chimera, loss of the 3WJ site has a moderate impact on regula-
tory activity, whereas a similar mutation in the PK site conferred
a dramatic loss in THF-dependent transcriptional attenuation.
These data reveal that the PK site is the primary regulatory site
with the 3WJ playing a supporting role (Trausch et al., 2011).
These findings suggest that binding affinity is not perfectly
correlated to regulation—there are features of the THF-RNA206 Chemistry & Biology 21, 205–216, February 20, 2014 ª2014 Elseinteraction that do not contribute to binding but are critical for
regulatory activity. To investigate this phenomenon, we probed
the THF riboswitchwith a series of THF, pterin, purine, andpyrim-
idine analogs chosen to interrogate different features of the
effector. We were also able to take advantage of the wealth of
antifolate therapeutics (Gonen and Assaraf, 2012) to further this
analysis. Using a combination of structural, calorimetric, and ac-
tivity measurements, we clearly reveal that the pABA moiety
plays a significant role in promoting regulation. Surprisingly, an
alternative small-molecule-binding mechanism is also possible
in which adenine and its analogs 2,6-diaminpurine (DAP) and
2-aminopurine (2AP) bind to the PK site in a reverse orientation
relative to pterin and guanine. Although this enables DAP to
bind to the RNA with 26-fold higher affinity than THF, this com-
pound is particularly ineffective at promoting regulatory activity.
Because riboswitches have been suggested to be potentially
important targets for novel antimicrobials, understanding the
disconnect between theeffector’s affinity for theaptamer domain
of the riboswitch and regulatory activity mediated by the down-
stream secondary structural switch should highlight challenges
and yield new insights into how to approach this problem.
RESULTS
The Majority of THF Riboswitches Bind Two Ligands at
Distinct Sites
It has been proposed that binding two molecules of the
aptamer domain is not a universal feature of the THF family ofvier Ltd All rights reserved
Figure 2. The Majority of, But Not All, THF Riboswitches Contain
Two Sites
(A) ITC titrations of Streptococcus mutans (Smu) and Eubacterium siraeum
(Esi) THF riboswitch binding to 6S-folinic acid. Data generated from three
independent titrations. Error represents SD.
(B) A few phylogenetic representatives of P3, which contains the three-way
junction binding (3WJ) site. Smu is an example of a P3 that represents the
majority of THF riboswitches containing a consensus THF binding site.
Lactobacillus saliva (Lsa), Lactobacillus reuteri (Lre), and Streptococcus
sobrinus (Sso) all contain sequence variations in P3 stems inconsistent with
binding at the 3WJ site.
(C) ITC titration of Streptococcus sobrinus (Sso) THF riboswitch binding
6S-folinic acid, revealing binding to a single site.
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observed in the structure of the Eubacterium siraeum (Esi) THF
riboswitch (Huang et al., 2011) might represent a subset of this
family that only binds the effector to the three-way junction site
(Serganov and Patel, 2012). This is in contrast to the observation
that the conservation of bases in direct contact with THF at the
PK site is nearly universal—including the Esi variant. Further,
the authors of the structural study of the Esi variant did not pre-
sent any solution data in support of the claim of a single binding
site. Therefore, we titrated the EsiTHF aptamer with the THF
analog folinic acid by isothermal titration calorimetry (ITC) to
verify its binding stoichiometry. Consistent with the SmuTHF
receptor structure, the EsiTHF receptor binds two equivalents
of ligand, with nearly the same apparent KD (Figure 2A). These
data strongly suggest that the lack of the PK site in the Patel
crystal structure is artifactual.
Despite the above finding, there may exist a subset of THF
riboswitches with only a single site within the pseudoknot.Chemistry & Biology 21, 205Recent expansion of THF riboswitch sequences available in
Rfam 11.0 revealed a subset of aptamers with sequence varia-
tion at the 3WJ site that is expected to disrupt binding. These
variants do not have the equivalent of the U25/C53 juxtaposition
at the 50-side of the P3 helix that forms the 3WJ site (Figure 2B).
To investigate whether these variants bind only a single THF, we
tested Streptococcus sobrinus, a sequence containing a
representative C53G variation. This RNA binds THF with a KD
of 2.4 ± 0.5 mM and an n value of 1.0 ± 0.1 (Figure 2C). This
demonstrates that although the majority of THF riboswitches
exhibit a sequence consistent with binding two ligands, there
is a subset of sequences that binds only one THF molecule at
the critical regulatory PK site. Thus, the 3WJ site is not an es-
sential feature of the THF family—only the PK site. Still, the
conclusions that binding and regulation of this receptor based
upon the two-site model are more representative of the family,
and all further analysis of the THF riboswitch is considered in
light of the two-site structure that represents the vast majority
of RNAs in this family (Trausch et al., 2011).
The Reduced Pterin Moiety Is the Primary Determinant
of High-Affinity Binding and Regulatory Activity
The central binding feature at both sites is that RNA-THF con-
tacts are mediated primarily through the pterin moiety with little
apparent contribution from either the pABA or glutamyl groups
(Figures 1D and 1E). To further define the role of functional
groups, we interrogated the structure and activity of the ribos-
witch with a series of THF, pterin, and purine analogs. In contrast
to previous studies, we took care to use the same, or very similar,
buffer and temperature conditions in our single-turnover in vitro
transcription assay and ITC conditions (70 mM buffer [pH 8.0],
70 mM NaCl, and 2.5 mM MgCl2 at 37
C) to correlate ligand
binding and regulatory activities.
The moderate importance of the pABA and glutamyl moieties
is exhibited through calorimetric measurements of the THF-RNA
interaction. In our original study, we obtained THF as amixture of
the 6S and 6R epimers, whereas in biology THF exists exclu-
sively in the 6S conformation (Illarionova et al., 2002). This
mixture yielded a 2:1 THF:RNA binding stoichiometry with no
indications that the RNA was discriminating between the two
epimers. However, modeling of 6R-THF into the crystal structure
of the bound state suggests that this epimer must adopt an
extreme pucker in the pterin ring to yield a conformation that
enables pABA-RNA contacts at either site (Figure S1 available
online). To clarify this issue, we obtained purified 6S-THF along
with 6R-THF and measured the binding and regulatory activity
(Table 1). 6S-THF and 6R-THF bind the receptor with similar
affinities: 13 ± 1 mM and 19 ± 2 mM, respectively. However, in a
single-turnover in vitro transcription assay under the same buffer
and temperature conditions, these compounds display a greater
difference in the concentration required to elicit the half-maximal
regulatory response (referred to as T50). 6S-THF yielded a T50 of
32 ± 1 mM, whereas the 6R-epimer showed a moderately, but
significantly, higher T50 (110 ± 10 mM). This demonstrates that
interactions between the pABA moiety and the RNA contribute
to stabilizing the receptor domain in a fashion that prevents the
competing antiterminator stem-loop structure from forming.
Attempts to crystallize the receptor with purified 6S-THF and
6R-THF in high concentrations of reducing agent (100 mM–216, February 20, 2014 ª2014 Elsevier Ltd All rights reserved 207
Table 1. Affinity and Transcriptional Regulation by THF and THF
Analogs
Ligand KD (mM) n T50 (mM)
Relative
T50/KD
6S-tetrahydrofolate 13 ± 1 1.9 ± 0.1 32 ± 1 2.5
6R-tetrahydrofolate 19 ± 2 2.1 ± 0.1 110 ± 10 5.8
6S-folinic acid 9.6 ± 0.3 2.3 ± 0.1 19 ± 1 2.0
dihydrofolate 23 ± 1 2.0 ± 0.1 89 ± 6 3.9
tetrahydrobiopterin 18 ± 3 1.9 ± 0.1 190 ± 20 10
6,7-dimethyl-
tetrahydrobiopterin
57 ± 3 2.1 ± 0.2 590 ± 30 10
7-deazaguanine 66 ± 1 2.0 ± 0.1 690 ± 20 10
Pemetrexed 110 ± 10 ND >10,000 NA
Lometrexol 37 ± 2 1.9 ± 0.2 190 ± 20 5.1
2,6-diaminopurine 0.5 ± 0.1 1.0 ± 0.1 130 ± 10 260
adenine 8 ± 1 1.2 ± 0.1 2,500 ± 800 310
2-aminopurine 26 ± 3 0.9 ± 0.1 >10,000 NA
8-aminoadenine 160 ± 20 1.1 ± 0.1 >10,000 NA
6-hydroxy-2,4,5-
triaminopyrimidine
84 ± 5 1.8 ± 0.1 1,400 ± 200 780
Error in KD and n represents SD of three independent experiments.
Error in T50 represents the error in the fit of the average of three indepen-
dent experiments. ND, not determined because of solubility limitations;
NA, not applicable.
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in crystals, but analysis of the diffraction data revealed that in
both cases oxidation led to the cleavage of the pABA/glutamyl
moieties (Reed and Archer, 1980).
To address this issue, we looked to a more oxidation-resistant
form of THF, folinic acid (5-formyl-THF or FA; Figure 3). This
compound is a naturally occurring intermediate of THF (Kariluoto
et al., 2010) and also a drug (leucovorin) used to ease the side
effects of the antifolate chemotherapeutic methotrexate
(Keshava et al., 1998). We have previously shown that folinic
acid binds the THF riboswitch at both sites with high affinity
(Trausch et al., 2011). In an effort to advance our understanding,
we obtained purified 6S-folinic acid (6S-FA, a kind gift from
Merck). We were able to obtain high-quality crystals of 6S-FA
bound to the riboswitch. The structure was very similar to the
one solved using a mixture of epimers but showed better density
for the pABA and glutamic acid of FA (Figures 1D, 1E, and S2).
We observed an affinity for 6S-FAby ITC of 9.6 ± 0.3 mM(Table 1).
The data showed a 2:1 THF:RNA stoichiometry but a single
apparent binding curve reflecting near equivalent binding sites.
In vitro transcription revealed a T50 of 19 ± 1 mM (Figure 4),
making it amore effective regulator than 6S-THF. It is not surpris-
ing that a modification at the N5 position is easily tolerated within
the binding pocket. In the cell, THF exists in a variety of forms
such as 5-methyl-THF, 5-formyl-THF (FA), and 5,10-methenyl-
THF, and likely the THF riboswitch recognizes all these forms
(Kariluoto et al., 2010). The ability of 6S-folinic acid to terminate
transcription was also tested with mutants that knock out either
binding site (U7C for PK site and U25C for 3WJ site). These data
are consistent with previous results using a mixture of (6S,6R)-
folinic acid epimers, in that knocking out the PK side is much208 Chemistry & Biology 21, 205–216, February 20, 2014 ª2014 Elsemore deleterious to the switch than is knocking out the 3WJ (Fig-
ure 4). However, we do note that the U7Cmutant was previously
observed to be 100-fold lower activity than wild-type (Trausch
et al., 2011), whereas, in the current study, it is completely
inactive. This difference may be attributable to the use of the
purified 6S-FA epimer in these experiments rather than the
mixture of epimers used previously as well as minor changes
to the transcription conditions (higher nucleotide triphosphate
[NTP] concentration in the current study). Notably, the Hill
coefficient (nH) is much higher with both sites compared to the
U25C mutant containing only the PK site, indicating a strongly
cooperative regulatory response.
The finding that the pABA moiety plays a role in regulation is
further supported by comparable measurements with dihydrofo-
late (DHF), the partially reduced form of THF. In DHF, the N8 of
the pterin ring is reduced such that it still forms a critical
hydrogen bond with residue U7. However, N5 is not reduced
such that C6 remains sp2 hybridized (Figure 3), likely disallowing
full van der Waals interactions between the pABA moiety and
RNA. Consistent with this, we find that DHF binds the RNA
with about two-fold lower affinity than 6S-THF and a higher
T50; these values are comparable to 6R-THF (Table 1).
To further assess the role of the pABA/glutamyl moieties in
binding and regulation, we examined a set of compounds that re-
move in part or wholly these groups. Tetrahydrobiopterin (BH4) is
a common reduced pterin in biology in which the pABA and glu-
tamyl moieties are replaced by a propylene glycol moiety at the
C6 position (Figure 3). BH4 binds with a KD only slightly higher
than 6S-THF, strongly supporting that the pABA/glutamyl
moieties contribute marginally to binding (Ames et al., 2010).
This is rather remarkable considering the pABA/glutamyl makes
up more than 50% of the molecular weight of THF and is in stark
contrast to the majority of riboswitches in which most, if not the
entirety, of the effector is directly recognized (Serganov and
Nudler, 2013). However, BH4 has a T50 of 190 ± 20 mM, or about
10-fold higher than its KD. The structure of the THF riboswitch
bound to BH4 shows that the placement of the pterin ring in
BH4 is identical to that of THF, but the propylene glycol does
not interact with the RNA in either binding site, as indicated by
the very weak electron density in this region (Figures 5A and 5B).
A synthetic ligand similar to BH4 is 6,7-dimethyl-tetrahydrop-
terin (DMPH4). It should be noted that this compound is available
only as a mixture of the four diastereomers at the 6 and 7 posi-
tions (Figure 3). DMPH4 shows a KD of 57 ± 3 mM and a stoichi-
ometry of 2:1 DMPH4:RNA (Table 1). The observed affinity is
weaker than 6S-THF or BH4, which might be because this com-
pound possesses two chiral centers that have no specific
distinction. It is possible that some of the diastereomers in this
mixture bind more poorly than others and that an averaged affin-
ity is observed by ITC. Similar to BH4, the T50 for DMPH4 was
10-fold higher than the KD. Although the crystal structure
showed density in both the PK and 3WJ sites corresponding to
the ring system, only poor density was observed for the methyl
groups, likely resulting from the bound ligand at both sites being
a mixture of all diastereomers (data not shown).
In our original study, we noted that guanine has a similar
pattern of hydrogen bond donors and acceptors as the reduced
pterin ring of THF (Trausch et al., 2011). In exponentially growing
E. coli guanine is found at a relatively high concentration ofvier Ltd All rights reserved
Figure 3. Ligands Used in Binding and Tran-
scription Termination Studies
The R group in select compounds represents the pABA
attached to L-glutamic acid (lower right) found in folate
and its natural derivatives.
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Figure 4. The Role of the Two Binding Sites in Transcription
Regulation
(A) Example of an in vitro transcription titration using 6S-folinic acid (0 to 3mM)
and the quantification of this data. Read-through (RT) and termination (Term)
products were separated using a 6% denaturing PAGE.
(B) Graph of quantified titrations done with wild-type (WT), U7C, U25C, and
U7C/U25C. Error bars represent SD based on three independent experiments.
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effector of the THF riboswitch within the cell. For example, the
glmS riboswitch integrates signal from two distinct metabolites,
one as an activator of mRNA cleavage and several as inhibitors
to elicit the appropriate regulatory response to the global meta-
bolic state of the cell (Watson and Fedor, 2011). To investigate
this hypothesis, we previously tested 7-deazaguanine (7DG, a
water-soluble analog of guanine) for affinity and transcriptional
regulation (Trausch et al., 2011). Data showed that 7DG binds
with high affinity, but poorly regulates transcription (Trausch
et al., 2011). Unfortunately, in the previous study, the KD and
T50 measurements were not taken under buffer/temperature-
matched conditions, complicating the comparison. Under the
conditions of this study, 7DG binds with a KD of 66 ± 1 mM and
exhibits a T50 of 690 ± 20 mM (Table 1). Like BH4 and DMPH4,
7DG has a T50 10-fold higher than the KD, again reflecting the
loss of interactions mediated by the pABA/glutamyl moieties.
The structure of the THF riboswitch was solved in complex
with 7DG (Figures 5C and 5D). 7DG is observed bound to both
the 3WJ and PK sites, making a set of hydrogen-bonding
interactions to the RNA analogous to reduced pterin. This struc-
ture confirms the previous hypothesis that guanine and certain
derivatives such as 7DG are able to engage the riboswitch, but
do not regulate under biologically relevant guanine concen-
trations. Instead, under physiological conditions, intracellular
guanine may act as a competitive inhibitor of regulation such
that higher THF concentrations are required to downregulate
gene expression.
A pyrimidine compound is also able to productively bind the
THF riboswitch. The purine riboswitch, which uses a similar set210 Chemistry & Biology 21, 205–216, February 20, 2014 ª2014 Elseof ligand-RNA contacts for recognition as the THF riboswitch,
is capable of binding several pyrimidine analogs (Dixon et al.,
2010; Gilbert et al., 2006a; Mulhbacher et al., 2010). Within
a series of pyrimidine analogs tested, 2,4,6-triaminopyrimi-
dine, 2,4,5,6-tetraaminopyrimidine, 2,4-diamiopyrimidine, and
a 5-member ring compound 5-aminoimidazole-4-carboxamide
all failed to bind (data not shown). Conversely, 6-hydroxy-
2,4,5-triaminopyrimidine (Figure 3) binds the THF aptamer with
a modest KD of 84 ± 5 mM and a 2:1 stoichiometry, similar to
the values observed for 7DG (Table 1). The T50 is 1,400 ±
200 mM, 16-fold higher than the KD, comparable to that of
BH4 and DMPH4 (Table 1). Although we were able to obtain
crystals of this complex, they were of extremely poor quality
and not suitable for diffraction studies. Thus, although the orien-
tation of 6-hydroxy-2,4,5-triaminopyrimidine in the binding sites
is unknown, it is possible that the hydrogen bonding is similar to
interactions made by 7DG.
Antifolate Drugs Are Able to Bind and Regulate the THF
Riboswitch
A number of drugs have been developed over the last half
century that target enzymes involved in THF synthesis or THF-
related pathways (Gonen and Assaraf, 2012). These compounds
are mainly anticancer agents that target proteins such as
dihydrofolate reductase, thymidylate synthase, and glycinea-
mide ribonucleotide formyltransferase (Gonen and Assaraf,
2012). Many of these compounds are designed to closely mimic
THF and therefore might represent a rich pool of potential effec-
tors of the THF riboswitch.
Lometrexol (DDATHF), a compound developed for the treat-
ment of cancer (Gonen and Assaraf, 2012), has a structure
with the greatest similarity to THF and folinic acid. This com-
pound replaces N5 and N10 with carbons, and the lack of N5
prevents the oxidative loss of the N8 hydrogen (Figure 3), which,
like folinic acid, might improve its performance. Lometrexol
binds to the THF riboswitch with an affinity of 37 ± 2 mM and reg-
ulates transcriptional termination with a T50 of 190 ± 20 mM (Ta-
ble 1). The 5-fold higher T50 relative to KD is similar to 6R-THF,
suggesting that the C5 and/or C10 substitutions have a delete-
rious effect. One possibility is that conjugation of N10 with the
benzyl ring in THF restricts conformational flexibility of the
pABA/glutamyl moiety, enabling it to position the pABA moiety
optimally for interacting with the RNA at each site. The additional
conformational freedom in Lometrexol has the same effect of the
6R epimer of THF that prohibits these interactions.
Pemetrexed (Alimta), a rationally designed drug used in the
treatment of lung cancer (Gonen and Assaraf, 2012), replaces
the pterin moiety with 7DG and N10 with a methylene group (Fig-
ure 3). Although 7DG is a poor regulator of transcriptional atten-
uation, the presence of the pABA/glutamyl moiety might improve
activity. However, Pemetrexed exhibits one of the poorest affin-
ities tested (KD = 110 ± 10 mM) and is almost completely unable
to terminate transcription (T50 R 10 mM). The 100-fold differ-
ence between KD and T50 is far greater than that observed for
7DG, indicating that the pABA/glutamyl moiety in the context
of a guanine scaffold is deleterious. A crystal structure of the
Pemetrexed-RNA complex revealed that in the 3WJ site,
Pemetrexed is bound almost identically as THF (Figures 5E
and 5F); the purine ring is correctly positioned, and there isvier Ltd All rights reserved
Figure 5. Structure of the THF Riboswitch Bound to a Set of Analogs
(A and B) Structure of tetrahydrobiopterin (BH4) bound to the three-way junction binding site (A) and the pseudoknot binding site (B).
(C and D) Structure of 7-deazaguanine (7DG) bound to the three-way junction binding site (C) and the pseudoknot binding site (D).
(E and F) Structure of Pemetrexed (Pem) bound to the three-way junction binding site (E) and the pseudoknot binding site (F).
For all structures, the electron density from a 2Fo-Fc simulated annealing omit map (calculated using a model in which all of the illustrated nucleotides and ligand
were omitted from the model) contoured at 1s is shown in gray.
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purine ring is also correctly positioned, but there is no density to
support the pABA in any conformation. The observed disorder of
the pABA/glutamyl moiety likely reflects C9 being coplanar with
the purine ring along with the greater conformational flexibility
imparted by C10. This observation may suggest that the key
interaction for regulation is between the pABA moiety and A80
in the PK site; the analogous stack with G68 in the 3WJ site is
not as important.
Methotrexate is a commonly used antifolate in the treatment of
many cancers and autoimmune disorders (Gonen and Assaraf,
2012). Methotrexate and many antifolate therapeutics exhibit
modifications to the pterin ring and the pABA/glutamyl moiety
relative to THF. In the case of methotrexate, these modifications
come in the form of an amino group replacing the carbonyl
oxygen of the pterin, a methyl group on N10, and the pterin
ring being fully oxidized (Figure 3). These deviations from THF
make the pattern of hydrogen bond donors and acceptors in
this compound incompatible with either binding pocket. Not
surprisingly, methotrexate does not bind to the THF riboswitch
or terminate transcription, and it is very likely that similar antifo-
lates such as pralatrexate, raltiterxed, trimetrexate, piritrexim,
and talotrexin also do not interact with the THF riboswitch.Chemistry & Biology 21, 205Retro-Binding of Adenine and Derivatives to the THF
Riboswitch
Given the above result with methotrexate, it was a great surprise
to find that adenine and one of its derivatives, 2,6-diaminopurine
(DAP), bind the THF riboswitch more tightly than 6S-folinic acid.
Likemethotrexate, the loss of hydrogen bonding to U42 in the PK
site (Figure 1C) or C53 in the 3WJ in adenine and its derivatives
would be expected to be a significant challenge for high-affinity
binding. To the contrary, DAP, 2-aminopurine (2AP), and adenine
(Ade) all bind with affinities either higher or comparable to
6S-THF (Table 1). The affinity of DAP is most striking (KD =
0.5 ± 0.1 mM) in that it is 20-fold higher than 6S-folinic acid.
However, ITC also revealed that these compounds bind the
THF aptamer with a 1:1 ligand:RNA stoichiometry, indicating
that they productively bind only one site. Comparing the regula-
tory activity of 1 mMDAP for the wild-type aptamer against point
mutants that abrogate THF binding to the PK site (U7C), the 3WJ
site (U25C), or both (U7C and U25C) revealed that DAP only
interacts with the PK site (Figure 6A).
The finding that DAP productively binds to the riboswitch
appears to be inconsistent with the lack of binding seen with
methotrexate, whose pterin moiety has a similar pattern of
hydrogen bond donors and acceptors. To understand this–216, February 20, 2014 ª2014 Elsevier Ltd All rights reserved 211
Figure 6. 2,6-Diaminopurine as a Binder and Effector of the THF Riboswitch
(A) PAGE separation of the terminated (Term) and read-through (RT) products from in vitro transcription done in the absence of ligand as well as 1 mM of folinic
acid (FA), 2,6-diaminopurne (DAP), adenine (Ade), and 2-aminpurine (2AP) in the context of the WT, U7C (DPK), U25C (D3WJ), and U7C/U25C (DPK+D3WJ)
variants.
(B and C) The structure of the pseudoknot binding site bound to DAP (B) and adenine (C). Simulated annealing omit map is shown in gray, calculated in the same
fashion as those in Figure 5.
(D) The overlay of two structures of dihydrofolate reductase bound to folate (Bystroff et al., 1990) (red) and methotrexate (Bolin et al., 1982) (blue).
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bound to DAP. No electron density consistent with ligand was
observed in the three-way junction site. Conversely, strong elec-
tron density was observed adjacent to U7, confirming binding to
the PK site. More strikingly, the orientation of the DAP in the PK
site is rotated180 within the binding pocket relative to the ring
systems of folinic acid and 7DG (Figure 6B). This orients the
Watson-Crick face of DAP away from U7/U35/U42, such that it
makes no hydrogen bonds with the RNA. Instead, it employs
the Hoogsteen and sugar edges of the nucleobase to interact
with the RNA. The crystal structure of Ade bound reveals the
same reverse binding mechanism as DAP (Figure 6C). Superim-
position of the DAP-bound structure on that of folinic acid or 7DG
reveals that the RNA does not undergo significant confor-
mational change to accommodate binding in the reverse orienta-
tion. This suggests that the PK site is rigid andmay not be able to
adopt alternative conformations to accommodate small mole-
cules with different patterns of hydrogen bond acceptors and
donors.
DAP binds the THF riboswitch with remarkable affinity but fails
to act as an equally efficient effector of transcriptional regula-
tion. DAP terminates transcription with a T50 of 130 ± 10 mM,
approximately 250-fold higher than the KD. DAP has two disad-
vantages in acting as an effector for the THF riboswitch. First, it
does not have a pABAmoiety, which in the case of BH4, DMPH4,
and 7DG comes at a 10-fold reduction in T50 relative to KD.
Second, DAP binds only at one site, which results in an addi-
tional 5-fold reduction in T50 in the SmuTHF aptamer. These
effects added together may contribute to the drastic difference212 Chemistry & Biology 21, 205–216, February 20, 2014 ª2014 Elsein KD and T50 seen with DAP, adenine, and 2AP. Like guanine
(see above), it is conceivable that adenine could act as a
competitive inhibitor to FA-dependent transcriptional termina-
tion. It is estimated that the intracellular adenine concentration
in rapidly dividing E. coli is 1.5 mM (Bennett et al., 2009), which
is not substantially below the observed affinity for adenine
binding to the PK site.
DISCUSSION
The structure of the THF riboswitch revealed several unusual
aspects of the aptamer distinguishing it from other riboswitches.
Uniquely, this aptamer contains two binding sites (Trausch et al.,
2011). By calorimetry, the RNAs used in both crystallographic
analyses bind two equivalents of THF; the observation of only
a single site in one structure (Huang et al., 2011) is an artifact
of strand swapping within the crystal. However, this is not a
universal feature of the THF riboswitch family. Inspection of an
expanded phylogenetic alignment of almost 600 sequences
available in Rfam 11.0 reveals that some Lactobacilli, Strepto-
coccus, and Clostridium species harbor THF riboswitches that
have sequence variations that ablate the 3WJ site. Unexpect-
edly, the SsoTHF aptamer that only binds one molecule of THF
has a higher affinity for THF than the SmuTHF aptamer. This
could be a result of stabilizing P3 with a G$U base pair in place
of the C/U juxtaposition that binds THF, enabling the 3WJ to
be organized without the assistance of THF binding. Thus, the
3WJ site is not essential for biological function. One explanation
of why an aptamer would evolve two binding sites is a selectionvier Ltd All rights reserved
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ative systems are ubiquitous in protein-based regulatory mech-
anisms, and it should be no surprise that RNA has evolved a
similar mechanism. A second hypothesis relates to the cotran-
scriptional nature of regulation. In this model, during transcrip-
tion of the aptamer domain, the 3WJ site is formed first, allowing
it to bind THF first and facilitate organization of the PK and
increasing the rate of association of THF to the regulatory site.
Thus, the 3WJ site acts as a folding center that makes the
kinetics of ligand binding and the coupled regulatory response
more favorable.
The other feature of the THF riboswitch is that it primarily
recognizes only one of the three main moieties—the pterin—
in reduced folates. In contrast, many riboswitches almost
completely encapsulate their ligand, usually through a confor-
mational change coupled to the binding event, and as a conse-
quence recognize almost all features of their effector (Batey
et al., 2004). In this study we examined THF in greater detail
to reveal potential minor contributions made by the pABA/
glutamyl moieties to binding and regulation. Our data clearly
show that although these groups do not contribute substan-
tially to binding energy, the pABA group significantly contrib-
utes to regulatory activity. Differences between binding and
regulatory efficiency have also been observed in the lysine
riboswitch (Garst et al., 2012). For example, the natural effector
lysine has a T50 to KD ratio of 1.0 (under transcription condi-
tions of 50 mM NTPs) such that binding and regulation occur
at the same concentration. The close derivative L-lysine methyl
ester displays near equivalent binding affinity to lysine, but has
a T50 to KD ratio of 6. These observations can be explained in
several ways. First is that the kinetics of association and disso-
ciation can substantially influence a compound’s ability to
efficiently elicit a regulatory response. Because many ribos-
witches are proposed to be under ‘‘kinetic control’’ (Haller
et al., 2011; Wickiser et al., 2005), parameters such as kon
and koff of the ligand are expected to have significant effect
on the observed T50. We should note that although the
in vitro transcription assay cannot completely mirror cellular
conditions for a variety of reasons, the behavior of riboswitches
between the two sets of conditions is consistent (Ceres et al.,
2013a; Lemay et al., 2011; Tomsic et al., 2008).
An alternative hypothesis is that these analogs disrupt a set
of interactions between the ligand and RNA critical for the reg-
ulatory switch. In most riboswitches, the ligand binding site lies
adjacent to nucleotides at the 30-end of the aptamer domain
that are involved in the regulatory switch (Garst and Batey,
2009). It may be that certain contacts are crucial for stabilizing
the incorporation of the switching sequence (a sequence
element that is partitioned into either the aptamer domain or
the expression platform) into the aptamer domain, thereby
preventing formation of one of the alternative secondary struc-
tures in the expression platform. In the case of THF, the pABA
moiety forms van der Waals contacts on the ribose-phosphate
backbone around A80. This interaction may be sufficient to
reduce invasion of the expression platform into the aptamer
that would be required to form an alternative secondary struc-
ture. In the case of the lysine riboswitch, the carboxyl moiety
mediates binding of a potassium ion that interacts with nucle-
otides on the 30-side of the P1 helix that are also involved inChemistry & Biology 21, 205alternative secondary structure formation (Garst et al., 2008;
Serganov et al., 2008).
These data illustrate an important consideration in the devel-
opment of compounds that target riboswitches. Since the
discovery that these RNA elements are widely distributed in
bacteria and control expression of genes critical for survival
and virulence in some medically important pathogens, it has
been proposed that theymight be important new targets for anti-
microbial therapeutics (Blount and Breaker, 2006). In fact, it has
been demonstrated that the natural antimicrobial compounds
roseoflavin and pyrophosphate pyrithiamine acquire their anti-
bacterial properties from interactions with the flavin mononucle-
otide (FMN) and thiamine pyrophosphate (TPP) riboswitches,
respectively (Lee et al., 2009; Sudarsan et al., 2005). A number
of studies looking for compounds that could be potential ribos-
witch effectors have often focused on looking for high-affinity
binders (Deigan and Ferre´-D’Amare´, 2011; Guan and Disney,
2012). However, this approach has yielded a number of hits
that bind, but do not efficiently regulate the switch (Cressina
et al., 2011). This study would suggest that certain aspects of
the effector’s interaction with the RNA must be preserved for a
chemical analog to be able to also regulate the riboswitch.
Another surprise in this study is the observation of an alterna-
tive binding mode for adenine and two related compounds. In
binding studies exploring chemical analogs of the native effector
to riboswitches, all of the productive binders appear to bind to
the RNA in the orientation as the biological effector. For
example, every lysine (Garst et al., 2012; Wilson-Mitchell et al.,
2012), purine (Gilbert et al., 2006b), and thiamine pyrophosphate
(Thore et al., 2008) analog tested to date has shown that the
compound lies in the binding pocket in the same orientation
and conformation as the native ligand. However, in the search
for compounds that target a particular riboswitch family, it is
highly desirable to discover chemical scaffolds from which to
build novel classes of compounds. In screening purine com-
pounds that bind to the THF riboswitch, we uncovered DAP.
This molecule binds 26-fold more tightly than 6S-THF and in
an opposite orientation within the pseudoknot binding pocket.
Unfortunately, DAP regulates extremely poorly, likely because
of the facts that it is unable to form interactions outside of the
ring system like pABA (10-fold effect) and that DAP only binds
to one site (5-fold effect). Nonetheless, the Watson-Crick
face (e.g., N1) provides a starting point for the addition of chem-
ical features that could mimic the pABA moiety and restore
efficient regulatory activity. The reverse binding mechanism of
DAP is not unprecedented among proteins and is even seen in
proteins recognizing folates (Saraste and Musacchio, 1994).
Dihydrofolate reductase naturally binds folate and is inhibited
by methotrexate (Saraste andMusacchio, 1994). Although these
compounds sterically have a similar pterin ring system, the
hydrogen-bonding pattern that the ring systems present are
quite different (analogous to THF/7DG and DAP). As a conse-
quence, methotrexate is flipped within the binding pocket with
respect to folate (Figure 5D) (Bolin et al., 1982; Bystroff et al.,
1990). The observation of ‘‘retro-binding’’ by the similar DAP/
methotrexate ring systems to protein and RNA reinforces that
in the search for small molecules that target RNA, many of the
same principles and tools that have been developed for proteins
can be applied (Daldrop et al., 2011).–216, February 20, 2014 ª2014 Elsevier Ltd All rights reserved 213
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Riboswitches have been advanced as a potentially new
class of targets for antimicrobial therapeutics, because
they control genes essential for virulence and survival in
medically important pathogens. Further, riboswitches, by
virtue of containing a known small-molecule-binding
site, are important model systems for establishing the
approaches and methodologies for targeting RNAs with
novel compounds. In this work, we clearly establish that a
series of pterin, purine, and pyrimidine compounds can effi-
ciently bind the THF riboswitch, but are not able to fully reca-
pitulate the regulatory properties of the natural effector.
Importantly, several established antifolates that are used
to target folate-dependent mechanisms in humans are
able to bind and regulate riboswitch activity. This suggests
that there exists a pool of known protein-binding therapeu-
tics that might be employed to target RNA. Further, the
finding that adenine and several of its analogs bind the
switch in an alternative binding mechanism demonstrates
that an issue that complicates drug discovery in proteins
also must be considered in efforts to target RNA. Together,
these results highlight important issues in the development
of RNA targeting compounds.
EXPERIMENTAL PROCEDURES
RNA and Ligand Preparation
Transcription and purification of RNA was performed using methods
described previously (Reyes et al., 2009). Briefly, RNA was transcribed from
a DNA template generated by PCR using T7 RNA polymerase, and the
resulting RNA was purified with a 12% denaturing acrylamide gel. RNA was
visualized by UV shadowing, the band corresponding to full-length product
excised and eluted from the gel using the ‘‘crush-and-soak’’ method overnight
in 0.53 T.E. buffer (5 mM Tris-Cl [pH 8.0] and 0.5 mM EDTA [pH 8.0]) at 4C.
The supernatant was concentrated with a 10,000 molecular weight cutoff
centrifugal concentrator, exchanged three times into 0.53 T.E. to remove
urea, and passed through a 0.2 mm filter. RNA was stored at 80C until
use. All sequences used in this study are listed in Table S1. Oxygen-sensitive
ligands (6S-THF, 6R-THF, and DHF) were brought up in buffer and used imme-
diately to limit loss in activity.
Isothermal Titration Calorimetry
Calorimetric measurements of the equilibrium dissociation constant (KD) were
performed as previously described (Trausch et al., 2011). Prepared RNA was
dialyzed overnight against ITC buffer (70mMNa-HEPES [pH 8.0], 70mMNaCl,
2.5 mM MgCl2, and 1 mM DTT). Ligand was resuspended from solid stocks
with ITC buffer. The concentration of RNA and ligand used in a titration was
determined by attempting to achieve a c value greater than 10 but less than
100 (Gilbert and Batey, 2009). All titrations using a MicroCal iTC200 (GE
Healthcare) were run at 37C to match both temperature and buffer conditions
of the single-turnover transcription assay. Data were processed using the
MicroCal processing software Origin 7. High-purity samples of 6S-THF,
6R-THF, DHF, and 6S-folinic acid used in experiments were provided as a
generous gift by Merck & Cie.
Single-Turnover Transcription Assays
The chimeric riboswitch between the S. mutans folT THF aptamer domain
and B. subtilis metE expression platform used previously (Trausch et al.,
2011) was cloned into pUC19 and sequence verified. Transcription of the
riboswitch is driven by a strong T7A1 promoter to allow for efficient
initiation with E. coli RNA polymerase. Template DNA was synthesized by
PCR amplification from this plasmid and purified using the QIAGEN PCR puri-
fication kit.214 Chemistry & Biology 21, 205–216, February 20, 2014 ª2014 ElseSingle-turnover in vitro transcription was adopted from methods previously
described (Dann et al., 2007). 17.5 ml volume reactions were prepared contain-
ing 50 ng of DNA template, 12.5 ml of 23 transcription buffer (140 mM Tris-Cl
[pH 8.0], 140mMNaCl, 0.2mMEDTA [pH 8.0], 28mM b-mercaptoethanol, and
70 mg/ml BSA), 2.5 ml of 25 mMMgCl2, 0.5 mCi of [a-
32P]ATP, and 0.25 units of
E. coli RNA polymerase s70 holoenzyme (Epicenter). These solutions were
incubated at 37C for 10 min. Transcription was initiated by adding 7.5 ml of
NTP mix (75 mM final concentration in each NTP and 0.2 mg/ml heparin and
ligand at 3.333 concentration) and further incubated at 37C for 20 min. Tran-
scription was quenched by adding 25 ml RNA loading dye (95% volume for
volume [v/v] deionized formamide, 10 mM EDTA [pH 8.0], 0.25% weight for
volume [w/v] bromophenol blue, and 0.25% (w/v) xylene cyanol) followed by
raising the temperature to 65C for 3min. A 6%29:1 acrylamide:bisacrylamide
denaturing polyacrylamide gel was used to separate terminated and read-
through products. The gel was imaged with a phosphor screen (Molecular
Dynamics) and scanned with a Typhoon 9400. The bands were quantified
using ImageQuant 5.2 (Molecular Dynamics). Data were fit to a standard
two-state binding model with a Hill coefficient parameter using IGOR Pro 6
(WaveMetrics).
X-Ray Crystallography, Structure Solution, and Refinement
The Smu THF riboswitch aptamer domain in complex with various ligands was
crystallized using the hanging drop/vapor diffusion method. One microliter of
RNA mix (500 mM RNA and 1–2 mM ligand) was mixed with 2 ml of crystalliza-
tion buffer comprised of 6%–8% 2-methyl-2,4-pentanediol (MPD), 8-12 mM
spermine HCl, 40 mM sodium cacodylate (pH 7.0), 80 mM sodium chloride,
and 1 mM dithiothreitol. Hanging drops were incubated at 30C for 3–5 days
over 500 ml of 35% MPD. The resulting needle-like crystals were mounted
on a nylon loop and flash frozen in liquid nitrogen.
Data sets were collected at the Advanced Light Source (5.0.2). Data were
indexed, integrated, and scaled using iMosflm (Battye et al., 2011). Initial elec-
tron density maps were generated with molecular replacement using PHENIX
(Adams et al., 2010) with model 3SD1 (Trausch et al., 2011). All atoms corre-
sponding to solvent, metal ions, and ligand were removed. Bases in the
hydrogen-bonding plane of the ligands, aswell as those involved in base stack-
ing to the pABA, were also removed (U7, U35, U42, U25, C53, andG68). Model
refinement was performed using a combination of energy minimization, simu-
lated annealing, and atomic B-factor refinement, all done in PHENIX (Adams
et al., 2010). At each stage, high-temperature simulated annealing was
employed to reduce model bias (Bru¨nger and Rice, 1997). Following initial
refinement of the model used for molecular replacement, the deleted nucleo-
tides were rebuilt using Coot (Emsley et al., 2010). Solvent was subsequently
built automatically and edited manually. Finally, the ligand was modeled with
the aid of 2Fo-Fc and Fo-Fc maps; energy restraints for ligands were generated
using PHENIX eLBOW. Crystallographic data and refinement statistics are
given in Table S2. To validate that the crystallographic data supported the
placement of each ligand in the fully refinedmodel, 2Fo-Fc simulated annealing
omit maps were generated by removing the ligand as well as bases involved in
ligand binding. All figures of models and maps were completed with PyMol.
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